- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01453218
Safety Use of ATeGe in Liver Transplant Recipients With Pre-transplant Renal Dysfunction (ATG_HVH)
Single Centre, Prospective, Open, Non Controlled, Pilot Study for Efficacy and Security Evaluation of Low Nephrotoxicity Immunosuppression, Based on the Use of ATeGe in Liver Transplant Recipients With Pre-transplant Renal Dysfunction
Renal dysfunction in the context of liver transplantation is a major issue, with difficult patients' management and determining a worsened prognosis.
Physiopathologically pretransplant renal dysfunction is dependent on multifactorial causes, including hypoperfusion-derived functional renal insufficiency, hepatorenal syndrome or interstitial parenchymatous insufficiency. On top, intra- or post-transplant events, including hypoperfusion or calcineurin inhibitors nephrotoxicity may aggravate this situation.
At present MELD criteria favours allocation of organs to patients suffering from renal insufficiency, so at least 30% of the investigators liver transplant patients suffer from some degree of renal impairment pretransplant.
After liver transplant impaired renal function tends to recover partially or completely, unless advanced parenchymatous lesions are significantly involved as a major cause of renal dysfunction.
In this context, calcineurin inhibitors avoiding or sparing protocols may help in the recovery from renal insufficiency, improving long-term prognosis. The use of anti-CD25 antibodies is a good option, but provides a limited antirejection prophylaxis, limiting the use of these antibodies to a reduced cohort of liver transplant patients.
Polyclonal antibodies might provide an advantage in management of liver transplant patients with renal insufficiency, without increasing acute rejection episodes of the allograft efficacy and security evaluation of low nephrotoxicity immunosuppression, based on the use of ATeGe, in liver transplant candidates with pre-transplant renal dysfunction.
The aim of this study is to evaluate the efficacy and security use of immunosuppression based on ATeGe in liver transplant recipients with pre-transplant renal dysfunction.
Panoramica dello studio
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
-
Barcelona, Spagna, 08035
- Department of HPB Surgery and Transplants, Hospital Vall d´Hebron
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Patients with moderate pre-transplant renal dysfunction as defined serum creatinine levels higher than 1.5 mg/dl or eGFR (MDRD-4) <60ml/min.
- First liver transplant, including splits liver transplant.
- Patients aged 18-70 years
- Without a prior contraindication for protocol biopsy of allograft.
Exclusion Criteria:
- Multiorgan transplantation and/or liver transplant from DCD and/or with ABO incompatibility.
- Uncontrolled concomitant infections (including HIV seropositivity) and/or diarrhoea, vomiting or active gastric ulcer.
- Fulminant hepatic insufficiency as first indication for liver transplant
- Hemodynamic instability prior to liver transplant.
- Recipient presenting present or previous neoplasia, except for non-metastatic basal or squamous cutaneous carcinoma or localized hepatocarcinoma with diameter <5 cm or < 3 known lesions with diameter <3 cm.
- Intolerance to study medication.
- Patients having received vaccination with attenuated living vaccines within the previous 4 weeks.
- Severe leukopenia (< 1.2 X 10E9/L) and/or thrombocytopenia (< 50x10E9/L) and/or lymphocyte counts (CD2+/CD3+) less than 10 cells/µl.
- Significant comorbidity.
- Breastfeeding or female patients at fertile age without negative pregnancy test and accepting the use of reliable fertility control method.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Scienza basilare
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Nessun intervento: Basiliximab
Historical comparable cohort treated with Basiliximab 20mg iv administered at 0 and 4th day post-transplant
|
|
Comparatore attivo: ATeGe-Fresenius
|
Administered at 1 , 3, 5 and 7 day post-transplant at 2-3mg/kg with dose adjustment according to CD2/CD3 levels
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Renal function improvement after liver transplant
Lasso di tempo: Measurement will be performed at 1st, 2nd, 3rd, 4th, 5th, 6th, 7th, 14th and 28th day post-transplant, and 2nd, 3rd, 6th and 12th month post-transplant
|
Creatinine (mg/dL) and MDRD Glomerular Filtrate Rate (ml/min/1.73m2)
will be measured following the time frame described above
|
Measurement will be performed at 1st, 2nd, 3rd, 4th, 5th, 6th, 7th, 14th and 28th day post-transplant, and 2nd, 3rd, 6th and 12th month post-transplant
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Incidence of biopsy proven acute cellular rejection.
Lasso di tempo: Evaluation at 1st , 3rd, 6th, 9th and 12th month post-transplant
|
If liver dysfunction is detected, percutaneous liver biopsy will be performed and histological severity will be assed following BANF criteria
|
Evaluation at 1st , 3rd, 6th, 9th and 12th month post-transplant
|
Patient and graft survival rates after 12 months, causes of death and retransplant
Lasso di tempo: Evaluation at 1st , 3rd, 6th, 9th and 12th month post-transplant
|
Evaluation at 1st , 3rd, 6th, 9th and 12th month post-transplant
|
|
Relationship between ATeGe doses, immunological variables (lymphocyte counts) and clinical adverse events (acute rejection,infections, HCV recurrence and de novo tumor)
Lasso di tempo: Evaluation at 1st , 3rd, 6th, 9th and 12th month post-transplant
|
Evaluation at 1st , 3rd, 6th, 9th and 12th month post-transplant
|
|
Incidence and severity of HCV infection recurrence, based on clinical and histological criteria.
Lasso di tempo: Once liver dysfunction is detected and one year post-transplant by protocol.
|
Once liver dysfunction is detected and one year post-transplant by protocol.
|
|
Evaluation of metabolic complications (diabetes mellitus, arterial hypertension and dyslipidemia)
Lasso di tempo: Evaluation at 1st , 3rd, 6th, 9th and 12th month post-transplant
|
Evaluation at 1st , 3rd, 6th, 9th and 12th month post-transplant
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: ITXARONE BILBAO, PhD/MD, Department of HPB Surgery and Transplants, Hospital Vall d´Hebron (Barcelona, Spain)
- Cattedra di studio: CRISTINA DOPAZO, PhD/MD, Department of HPB Surgery and Transplants, Hospital Vall d´Hebron (Barcelona, Spain)
- Direttore dello studio: RAMON CHARCO, PHD/MD, Department of HPB Surgery and Transplants, Hospital Vall d´Hebron (Barcelona, Spain)
- Cattedra di studio: MONICA MARTINEZ, PhD/MD, Department of Inmunology, Hospital Vall d´Hebron (Barcelona, Spain)
- Cattedra di studio: GONZALO SAPISOCHIN, PhD/MD, Department of HPB Surgery and Transplants, Hospital Vall d´Hebron (Barcelona, Spain)
- Cattedra di studio: JOSE L LAZARO, MD, Department of HPB Surgery and Transplants, Hospital Vall d´Hebron (Barcelona, Spain)
- Cattedra di studio: HELENA ALLENDE, PhD/MD, Department of Histology, Hospital Vall d´Hebron (Barcelona, Spain)
Pubblicazioni e link utili
Pubblicazioni generali
- Uemura T, Schaefer E, Hollenbeak CS, Khan A, Kadry Z. Outcome of induction immunosuppression for liver transplantation comparing anti-thymocyte globulin, daclizumab, and corticosteroid. Transpl Int. 2011 Jul;24(7):640-50. doi: 10.1111/j.1432-2277.2011.01250.x. Epub 2011 Mar 23.
- Benitez CE, Puig-Pey I, Lopez M, Martinez-Llordella M, Lozano JJ, Bohne F, Londono MC, Garcia-Valdecasas JC, Bruguera M, Navasa M, Rimola A, Sanchez-Fueyo A. ATG-Fresenius treatment and low-dose tacrolimus: results of a randomized controlled trial in liver transplantation. Am J Transplant. 2010 Oct;10(10):2296-304. doi: 10.1111/j.1600-6143.2010.03164.x.
- Soliman T, Hetz H, Burghuber C, Gyori G, Silberhumer G, Steininger R, Muhlbacher F, Berlakovich GA. Short-term induction therapy with anti-thymocyte globulin and delayed use of calcineurin inhibitors in orthotopic liver transplantation. Liver Transpl. 2007 Jul;13(7):1039-44. doi: 10.1002/lt.21185.
- Soliman T, Hetz H, Burghuber C, Gyori G, Silberhumer G, Steininger R, Muhlbacher F, Berlakovich GA. Short-term versus long-term induction therapy with antithymocyte globulin in orthotopic liver transplantation. Transpl Int. 2007 May;20(5):447-52. doi: 10.1111/j.1432-2277.2007.00463.x. Epub 2007 Mar 2.
- Kim MJ, Tsinalis D, Franz S, Binet I, Gurke L, Mihatsch MJ, Steiger J, Thiel G, Dickenmann M. ATG-Fresenius or daclizumab induction therapy in immunologically high risk kidney recipients: a prospective randomized pilot trial. Ann Transplant. 2008;13(4):21-7.
- Bajjoka I, Hsaiky L, Brown K, Abouljoud M. Preserving renal function in liver transplant recipients with rabbit anti-thymocyte globulin and delayed initiation of calcineurin inhibitors. Liver Transpl. 2008 Jan;14(1):66-72. doi: 10.1002/lt.21309.
- Tector AJ, Fridell JA, Mangus RS, Shah A, Milgrom M, Kwo P, Chalasani N, Yoo H, Rouch D, Liangpunsakul S, Herring S, Lumeng L. Promising early results with immunosuppression using rabbit anti-thymocyte globulin and steroids with delayed introduction of tacrolimus in adult liver transplant recipients. Liver Transpl. 2004 Mar;10(3):404-7. doi: 10.1002/lt.20085.
- Dopazo C, Charco R, Caralt M, Pando E, Lazaro JL, Gomez-Gavara C, Castells L, Bilbao I. Low Total Dose of Anti-Human T-Lymphocyte Globulin (ATG) Guarantees a Good Glomerular Filtration Rate after Liver Transplant in Recipients with Pretransplant Renal Dysfunction. Can J Gastroenterol Hepatol. 2018 Aug 16;2018:1672621. doi: 10.1155/2018/1672621. eCollection 2018.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- ATG-IRA-HVH.10
- 2011-000691-34 (Numero EudraCT)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Insufficienza renale
-
National Cancer Institute (NCI)NCIC Clinical Trials Group; Southwest Oncology Group; Cancer and Leukemia Group BCompletatoCarcinoma a cellule renali a cellule chiare | Cancro a cellule renali in stadio III AJCC v7 | Cancro a cellule renali in stadio II AJCC v7 | Stadio I Renal Cell Cancer AJCC v6 e v7Stati Uniti, Canada, Porto Rico
-
National Cancer Institute (NCI)TerminatoCarcinoma a cellule renali a cellule chiare | Carcinoma a cellule renali metastatico | Cancro a cellule renali in stadio III AJCC v7 | Cancro a cellule renali in stadio IV AJCC v7 | Cancro a cellule renali in stadio II AJCC v7 | Stadio I Renal Cell Cancer AJCC v6 e v7Stati Uniti
Prove cliniche su ATeGe-Fresenius
-
Hospital Clinic of BarcelonaAstellas Pharma Inc; Fresenius AGTerminato
-
University Health Network, TorontoHeart and Stroke Foundation of OntarioCompletatoCardiopatia | Declino neurocognitivoCanada
-
Astellas Pharma China, Inc.CompletatoDestinatari di trapianto di reneCina
-
Kyungpook National University HospitalMinistry of Health & Welfare, Korea; Fresenius Medical Care KoreaCompletatoInsufficienza renale cronica | Disturbi associati alla dialisi peritonealeCorea, Repubblica di
-
YUAN Wei-jieSconosciuto
-
UConn HealthDialysis Clinic, Inc.; Nipro Medical CorporationCompletatoMalattia renale allo stadio terminale
-
Lawson Health Research InstituteWestern University, CanadaCompletatoProcedure cardiochirurgiche
-
Ullevaal University HospitalRikshospitalet University HospitalCompletatoCoagulazione extracorporea durante l'emodialisiNorvegia
-
IRCCS Policlinico S. MatteoItalian Association for Pediatric Hematology OncologySconosciutoPazienti pediatrici affetti da neoplasie ematologiche e idonei a sottoporsi a HSCT da un volontario non imparentatoItalia
-
Rigshospitalet, DenmarkSnedkermester Sophus Jacobsen and hustru Astrid Jacobsens Foundation; Danish... e altri collaboratoriCompletatoRisonanza Magnetica Cardiaca | Individui sani | Mappatura T1Danimarca